(Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met…
Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, in patients with advanced HER2+…
Aurion Biotech Reports Positive 12-Month Results from Phase 1/2 CLARA Trial of AURN001 in Corneal Endothelial Disease Aurion Biotech, a clinical-stage regenerative medicine company dedicated to restoring vision for millions of patients worldwide, today announced encouraging 12-month results from its…
Ono Pharmaceutical Announces Two-Year Results from Phase 3 MOTION Study of Vimseltinib in TGCT at ESMO 2025 Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that two-year efficacy and safety results from the…
Evvy, the world’s leading platform leveraging the vaginal microbiome to improve women’s health outcomes, today announced record growth and compelling new data demonstrating the transformative impact of its platform. Evvy now serves over 75,000 patients and partners with more than…
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced updated long-term results from the global Phase 3 MANEUVER trial, evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor, for the treatment…
Samsara Vision, a company dedicated to restoring vision and independence to patients living with late-stage, age-related macular degeneration (AMD) through advanced visual prosthetic devices, today announced the expansion of its ongoing Concerto clinical study evaluating the investigational Smaller-Incision New-Generation Implantable…
hape Memory Medical Inc., developer of the only commercially available volume-expanding shape memory polymer for endovascular embolization, has announced that it has reached 50% enrollment in its ongoing AAA-SHAPE Pivotal Trial. This milestone marks the successful treatment of the 90th…
Delix Therapeutics, a clinical-stage neuroscience company advancing a new generation of non-hallucinogenic neuroplastogens for the treatment of serious neuropsychiatric and neurodegenerative disorders, has announced the publication of a peer-reviewed study in ACS Chemical Neuroscience. The paper, titled “Zalsupindole is a…
Arcitecta, a pioneer in innovative data management software, recently joined leading research institutions and technology partners—including Spectra Logic, Wasabi, Cerabyte, and IQM—at the inaugural DATAKAMER 2025 event. Hosted by the Dana-Farber Cancer Institute in Boston, Massachusetts, this exclusive, one-day forum…